In the run up to our 2015 Drug Discovery Summit, we spoke with Juan-Miguel Jimenez, Vertex Pharmaceuticals and Araz Raoof, Janssen Pharmaceuticals to discuss their thoughts about the end of the era of the blockbuster drug and what the future of drug discovery research might look like.

Juan-Miguel Jimenez, Senior Director, Head of Chemistry UK, Vertex Pharmaceuticals

Juan-Miguel joined Vertex Pharmaceuticals (UK) as senior Project Leader and subsequently appointed Head of Chemistry in 2013 where he is currently working. He has developed leadership responsibilities for Kinase projects within several therapeutic areas, including cancer, immunology and CNS. At our 16th Annual Drug Discovery Leaders Summit Juan-Miguel will share a case study of the discovery of a clinical candidate for the treatment of cancer.

Click here to read our interview with Juan-Miguel.

Araz Raoof, Scientific Affairs and Analysis, Janssen Pharmaceuticals, Belgium

Araz is currently Scientific Affairs and Analysis lead at the Janssen Pharmaceutica Research and Development campus in Belgium. Prior to this role, she was a Vice President Global Functional Head of Community of Research Excellence & Advanced Technology (C.R.E.A.Te / Discovery Sciences) at Janssen Research & Development, also at Belgium.

Click here to read our interview with Araz.